Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents

INTRODUCTION: Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Nozaki, Keina, Matsushima, Hisashi, Obikane, Hiyo, Nishimoto, Ryohei, Tanaka, Ryo, Morishige, Takeru, Masuda, Tomoko, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622209/
https://www.ncbi.nlm.nih.gov/pubmed/37928277
http://dx.doi.org/10.1002/iju5.12611
_version_ 1785130491125432320
author Nozaki, Keina
Matsushima, Hisashi
Obikane, Hiyo
Nishimoto, Ryohei
Tanaka, Ryo
Morishige, Takeru
Masuda, Tomoko
Kume, Haruki
author_facet Nozaki, Keina
Matsushima, Hisashi
Obikane, Hiyo
Nishimoto, Ryohei
Tanaka, Ryo
Morishige, Takeru
Masuda, Tomoko
Kume, Haruki
author_sort Nozaki, Keina
collection PubMed
description INTRODUCTION: Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone marrow remains unclear. CASE PRESENTATION: We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium‐223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression‐free survival for 17 months after the initial diagnosis. CONCLUSION: These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow.
format Online
Article
Text
id pubmed-10622209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106222092023-11-03 Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents Nozaki, Keina Matsushima, Hisashi Obikane, Hiyo Nishimoto, Ryohei Tanaka, Ryo Morishige, Takeru Masuda, Tomoko Kume, Haruki IJU Case Rep Case Reports INTRODUCTION: Disseminated carcinomatosis of the bone marrow in prostate cancer is rare and has a poor prognosis. Although strong evidence suggests that novel hormonal agents improve the prognosis of metastatic prostate cancer, their effectiveness in cases of disseminated carcinomatosis of the bone marrow remains unclear. CASE PRESENTATION: We encountered two cases of prostate cancer with disseminated carcinomatosis of the bone marrow at the time of initial diagnosis. One patient was treated with enzalutamide, abiraterone, docetaxel, cabazitaxel, denosumab, and radium‐223 and died 38 months after the initial diagnosis. The other patient was treated with apalutamide and denosumab, and had progression‐free survival for 17 months after the initial diagnosis. CONCLUSION: These results suggest that novel hormonal agents may improve the prognosis of prostate cancer even in patients with disseminated carcinomatosis of the bone marrow. John Wiley and Sons Inc. 2023-08-04 /pmc/articles/PMC10622209/ /pubmed/37928277 http://dx.doi.org/10.1002/iju5.12611 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Nozaki, Keina
Matsushima, Hisashi
Obikane, Hiyo
Nishimoto, Ryohei
Tanaka, Ryo
Morishige, Takeru
Masuda, Tomoko
Kume, Haruki
Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title_full Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title_fullStr Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title_full_unstemmed Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title_short Two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
title_sort two cases of prostate cancer with disseminated carcinomatosis of the bone marrow treated with novel hormonal agents
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622209/
https://www.ncbi.nlm.nih.gov/pubmed/37928277
http://dx.doi.org/10.1002/iju5.12611
work_keys_str_mv AT nozakikeina twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT matsushimahisashi twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT obikanehiyo twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT nishimotoryohei twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT tanakaryo twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT morishigetakeru twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT masudatomoko twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents
AT kumeharuki twocasesofprostatecancerwithdisseminatedcarcinomatosisofthebonemarrowtreatedwithnovelhormonalagents

Ejemplares similares